Abstract YO32
Case summary
Prostatic rhabdomyosarcoma in adult is a uncommon disease of adult. There are few cases reported as adult rhabdomyosarcoma of prostate. Most of the cases present with advanced stage. Modality of treatment vary from that of pediatric counterpart. Moreover stage wise treatment for adult disease are not well defined. We presented a young adult case of rhabdomyosarcoma presented with acute retention of urine and severe lower abdominal pain. After evaluation we thought of prostatic rhabdomyosarcoma which was later confirmed by IHC study. As the case was metastatic during presentation panel of experts recommend neoadjuvant chemotherapy followed by surgery according to the response of the treatment. There is no clear treatment plan recommendation for this advance stage, but we planned to evaluate Doxorubicin and Ifosphamide regimen for clinical trial. Surprisingly the systemic therapy works and after 3 cycle there was a very small residue persist. After almost complete response we recommended to continue further 3 cycle. Though surgery and radiation therapy Is the mainstay of treatment we can recommend neoadjuvant chemotherapy for metastatic rhabdomyosarcoma of prostate in adult from our clinical experience.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract